NeoStem Inc., of New York, priced an underwritten public offering of 20 million shares of common stock at 50 cents apiece, seeking to generate $10 million

Pfizer Inc., of New York, presented results from a Phase III study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49

Inc., of Whitehouse Station, N.J., and Pfizer Inc., of New York, have entered a worldwide (except Japan) collaborative agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose co-transporter (SGLT2) inhibitor being evaluated for the treatment of Type II diabetes...Novartis Pharmaceuticals Corp., of East Hanover, N.J., part of Novartis AG, said it disputes the allegations made by the U.S. Attorney's Office for the Southern

New York-based Pfizer Inc

and spends about an hour responding to emails and scanning stories in the New York Times, Wall Street Journal and Boston Globe

Pfizer Inc., of New York, said the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for Xeljanz (tofacitnib citrate) for the treatment of adults with moderate to severe active rheumatoid arthritis

Total Value in 2013: $5,960.77M* Number of Deals in 2013: 93 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date FEBRUARY Ablynx NV (Ghent, Belgium) Spirogen Ltd. (London) ND Research collaboration to evaluate the potential of a cancer drug conjugate combining Spirogen's cytotoxic drugs, pyrrolobenzodiazepines and associated linker technology, with Nanobodies generated Ablynx will provide access to Nanobodies against an undisclosed target, and Spirogen will

Pfizer Inc., of New York, said that top-line data for a Phase IV trial of Celebrex (celecoxib) capsules or naproxen in juvenile idiopathic arthritis patients demonstrated no difference in changes to systolic blood pressure, the primary endpoint, and diastolic blood pressure, the secondary endpoint

Anterios Inc., of New York, a privately held aesthetic medicine and medical dermatology biopharmaceutical company, closed an $8.5 million corporate financing

New York-based Royalty Pharma, which has made a hostile bid of $7.3 billion for Elan, has explicitly alluded to this in an investor presentation: "If Elan management was raising a fund to go out and buy unknown companies and products around the globe, would you invest $4.4 billion with them

Amgen indicated that demand trends have not changed," wrote analyst Eric Schmidt, of New York-based Cowen and Co., in a research note, "but that much of the sequential decline in sales was due to late 2012 buy-ins by secondary customers ahead of Q1 price increases...Historically, first quarter product revenues have always been down, wrote analyst Robyn Karnauskas, of Deutsche Bank in New York, who added that her company is "excited about Amgen's pipeline with significant news flow" in the next year

Some of its rivals already have chalked up big pharma deals around in vivo antibody platforms, most notably Ablexis LLC, of San Francisco, which received backing from a consortium of five companies to develop its AlivaMab Mouse platform, including founding investor Pfizer Inc., of New York, all of which gained nonexclusive access to its technology

Bristol-Myers Squibb Co., of New York, announced interim Phase II data demonstrating sustained virologic response of up to 94 percent, in treatment-naïve, genotype 1 chronic hepatitis C patients, at time points ranging from four to 36 weeks post-treatment depending on the treatment group, in patients treated with combination regimens of daclatasvir, asunaprevir and BMS-791325

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair...plc, of Dublin, Ireland, said its board has determined that New York-based Royalty Pharma's offer to acquire the company for $11.25 or less per share substantially

Ironwood and partner Forest Laboratories Inc., of New York, completed enrollment in a Phase IIIb trial studying the guanylate cyclase-C agonist's effect on abdominal symptoms in patients with CIC

plc, of Dublin, Ireland, said its board has determined that New York-based Royalty Pharma's offer to acquire the company for $11.25 or less per share substantially undervalues the company...Ohr Pharmaceutical Inc., of New York, raised about $5.05 million from institutional and accredited shareholders through the exercise of Series B warrants

Some of its rivals already have chalked up big pharma deals around in vivo antibody platforms, most notably Ablexis LLC, of San Francisco, which received backing from a consortium of five companies to develop its AlivaMab Mouse platform, including founding investor Pfizer Inc., of New York, all of which gained nonexclusive access to its technology

Inc., of Whitehouse Station, N.J., entered into a nonexclusive deal with Bristol-Myers Squibb Co., of New York, to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus infection genotype 1

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Cevec Pharmaceuticals GmbH (Cologne, Germany) Yuhan Corp. (Seoul, South Korea) ND CAP-Technology licensing deal enabling Yuhan to use Cevec's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins Financial terms were not disclosed 12/21/12 GlaxoSmithKline plc (London) The University of Texas MD Anderson Cancer Center (Houston) $335 Research